Volatomic Insights provides a urine-based cancer screening service that utilizes spectroscopy and artificial intelligence to detect multiple cancers, including prostate cancer, from a single sample. This noninvasive approach enhances patient comfort while delivering accurate and timely diagnoses, facilitating early intervention and improved treatment outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer screening methods often involve invasive procedures or may only detect a limited number of cancer types. Blood-based tests, while less invasive than biopsies, still require venipuncture, which can be uncomfortable for patients. Existing screening approaches may also lack the sensitivity needed for early detection, leading to delayed diagnoses and potentially poorer treatment outcomes.
Solution
Volatomic Insights offers a non-invasive, urine-based cancer screening service that leverages spectroscopy and artificial intelligence to detect multiple cancers from a single sample. The process involves analyzing a patient-provided urine sample via spectroscopy, followed by AI-driven diagnostics to determine if the patient is cancer-positive or cancer-negative. This approach aims to provide accurate and timely diagnoses, facilitating early intervention and improved treatment outcomes while enhancing patient comfort and accessibility. By training advanced AI models against the totality of the spectra, the test aims to improve upon traditional methods that analyze individual biomarkers.
Target Audience
The primary target audience includes individuals seeking convenient and non-invasive cancer screening options, as well as healthcare providers looking for advanced diagnostic tools for early cancer detection.
Features
- Urine-based sample collection, eliminating the need for invasive procedures like blood draws or biopsies.
- Spectroscopy analysis to identify spectral signatures associated with various cancers.
- AI-powered diagnostic models trained on comprehensive spectral data for improved accuracy.
- Detection of multiple cancer types from a single urine sample.
- Results delivered in a timely manner to facilitate early intervention.